23andMe goes public using Richard Branson’s blank cheque companyDNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Share X23andMe goes public using Richard Branson’s blank cheque companyhttps://pharmaphorum.com/news/23andme-goes-public-using-richard-bransons-blank-cheque-company/
AZ closes $400 million Atacand sale to Germany’s CheplapharmAstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as Share XAZ closes $400 million Atacand sale to Germany’s Cheplapharmhttps://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/
BMS/Celgene merger payout evaporates as CVR deadline passesFormer Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three Share XBMS/Celgene merger payout evaporates as CVR deadline passeshttps://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
Royalty Pharma shares surge 59% after $2.2 billion IPOBiopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised Share XRoyalty Pharma shares surge 59% after $2.2 billion IPOhttps://pharmaphorum.com/news/royalty-pharma-shares-surge-59-after-2-2-billion-ipo/
Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel fileThe chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right Share XCelgene investors’ CVR payment looks rocky, as FDA rejects ide-cel filehttps://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/
COVID-19 candidate Actemra helps Roche to solid first quarterRoche shrugged off the impact of the coronavirus pandemic in the first-quarter with good sales growth across its Share XCOVID-19 candidate Actemra helps Roche to solid first quarterhttps://pharmaphorum.com/news/covid-19-candidate-actemra-helps-roche-to-solid-first-quarter/
